Boost for potential blockbuster

Posted 24 April 2024 AM

An Australian trial has shown significant benefits to adding Novartis' Pluvicto to Astellas' Xtandi in treating metastatic castration-resistant prostate cancer, with the authors saying it "has implications for the future use of theranostics in prostate cancer".

Pluvicto is currently being evaluated by the TGA. It has approval in the US for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) in patients who have been treated with androgen receptor pathway inhibition, such as Xtandi, and taxane-based chemotherapy.

To see the whole article, please login